Products
Platform
Research
Market
Learn
IPO
Compare Motilal Oswal Nifty MidSmall Healthcare Index Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.12 | 1.86 |
NAV | ₹10.64 | ₹40.22 |
Fund Started | 29 Oct 2024 | 25 Jun 2018 |
Fund Size | ₹29.52 Cr | ₹6437.36 Cr |
Exit Load | Exit load of 1%, if redeemed within 15 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
1.12
1.86
NAV
₹10.64
₹40.22
Fund Started
29 Oct 2024
25 Jun 2018
Fund Size
₹29.52 Cr
₹6437.36 Cr
Exit Load
Exit load of 1%, if redeemed within 15 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 2.37% | 3.31% |
3 Year | - | 26.49% |
5 Year | - | 18.90% |
1 Year
2.37%
3.31%
3 Year
-
26.49%
5 Year
-
18.90%
Holding Analysis
Equity | 99.88% | 97.10% |
Cash | 0.12% | 2.90% |
Equity
99.88%
97.10%
Cash
0.12%
2.90%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Fortis Healthcare Ltd. | 9.91% |
Lupin Ltd. | 8.83% |
Laurus Labs Ltd. | 6.91% |
Aurobindo Pharma Ltd. | 5.94% |
Alkem Laboratories Ltd. | 5.78% |
Glenmark Pharmaceuticals Ltd. | 5.29% |
Mankind Pharma Ltd. | 5.01% |
Biocon Ltd. | 4.17% |
Krishna Institute of Medical Sciences Ltd | 3.31% |
Ipca Laboratories Ltd. | 3.29% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Swapnil P Mayekar | Dharmesh Kakkad |
Start Date | 18 Nov 2025 | 23 Feb 2021 |
Name
Swapnil P Mayekar
Dharmesh Kakkad
Start Date
18 Nov 2025
23 Feb 2021
About Fund
Description | The scheme seeks to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index, subject to tracking error. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 29 Oct 2024 | 25 Jun 2018 |
Description
The scheme seeks to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index, subject to tracking error.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
29 Oct 2024
25 Jun 2018